9 Cardiovascular Risk Markers That Worsen Specifically at Menopause (And Which Tests to Request)
The thing that surprised me most was how fast these markers can move — we're talking within the first year or two after the final period. A lot of women assume heart disease is something to worry about in their seventies. The biology disagrees, and so does the research. Getting the right tests done now, while there's still a wide window to act, is one of the most useful things a woman can do for her future self.
Learn more about Rose →LDL Cholesterol — and the Particle Size That Actually Matters
LDL rises measurably in the perimenopause-to-postmenopause transition, with studies showing an average increase of 10–15 mg/dL that is attributable to estrogen loss rather than age alone. Estrogen normally upregulates LDL receptors in the liver, so when levels fall, clearance slows and LDL accumulates. Standard lipid panels report LDL concentration, but requesting an LDL particle number (LDL-P) or apolipoprotein B (ApoB) test gives a more accurate picture of actual cardiovascular risk, since small dense LDL particles are more atherogenic than large buoyant ones.
Triglycerides — Sensitive to Both Estrogen Loss and Lifestyle
Triglyceride levels rise during the menopause transition partly because estrogen normally enhances the clearance of very-low-density lipoproteins (VLDL), which carry triglycerides through the bloodstream. When estrogen declines, this clearance mechanism slows, and triglycerides accumulate — a shift that is compounded by the insulin resistance that often develops at the same stage. A fasting triglyceride level above 150 mg/dL is considered borderline high; levels above 200 mg/dL in a postmenopausal woman who had normal levels premenopausally are a meaningful signal worth investigating.
Lipoprotein(a) — the Risk Marker Most Doctors Never Order
Lipoprotein(a), written as Lp(a), is a genetically determined particle that is largely stable across adulthood — except that it rises significantly at menopause, by as much as 25% in some studies, likely driven by estrogen withdrawal. High Lp(a) is an independent risk factor for heart attack and stroke, and it is not captured by any standard lipid panel. The test is a simple blood draw (request it by name as "lipoprotein(a)") and needs to be done only once or twice in a lifetime since baseline levels are set by genetics, but the menopause-related rise makes the transition a critical time to check it.
HDL Cholesterol — When the 'Good' Cholesterol Stops Being Protective
HDL — often labeled the protective, "good" cholesterol — does not necessarily fall at menopause, but its function changes. Research indicates that postmenopausal HDL becomes less effective at reverse cholesterol transport, the process by which HDL carries cholesterol away from arterial walls back to the liver for disposal. This means a woman can have a numerically acceptable HDL level and still carry elevated cardiovascular risk, which is why HDL functionality — not just quantity — matters and why it is worth discussing with a clinician who goes beyond the standard panel.
Apolipoprotein B (ApoB) — One Number That Counts All the Bad Particles
ApoB is a protein that sits on the surface of every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a) — meaning one ApoB measurement counts all of them at once. Many cardiologists now consider ApoB a more reliable predictor of cardiovascular risk than LDL-C, particularly in women, who can have deceptively normal LDL readings while carrying a high burden of small, dangerous particles. Menopause-associated metabolic shifts tend to increase both particle number and the proportion of small dense LDL, making ApoB a particularly useful test to request during and after the transition.
Fasting Insulin and HOMA-IR — the Insulin Resistance Signal
Insulin resistance accelerates during perimenopause, driven by declining estrogen, disrupted sleep, and shifts in body fat distribution toward visceral (abdominal) fat. Standard metabolic panels check fasting glucose, but glucose can remain in the normal range for years while insulin is already elevated and compensation is quietly failing. Requesting a fasting insulin level alongside fasting glucose allows calculation of HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), a ratio that flags insulin resistance long before prediabetes appears on a standard lab — and insulin resistance is itself a significant independent cardiovascular risk factor.
High-Sensitivity C-Reactive Protein (hs-CRP) — Measuring Arterial Inflammation
CRP is a marker of systemic inflammation, and the high-sensitivity version of the test (hs-CRP) is sensitive enough to detect the low-grade chronic inflammation that predicts cardiovascular events. Estrogen has anti-inflammatory properties, so its decline at menopause is associated with a measurable rise in inflammatory markers including hs-CRP. An hs-CRP above 2 mg/L is associated with elevated cardiovascular risk in women, and because it is modifiable through lifestyle changes and, in some cases, hormone therapy, it is one of the more actionable markers on this list.
Arterial Stiffness and Blood Pressure — the Estrogen-Withdrawal Vascular Shift
Estrogen keeps blood vessels flexible by stimulating nitric oxide production, which causes arterial walls to relax and dilate. As estrogen declines, arterial stiffness increases — a change that is measurable using pulse wave velocity (PWV) testing, available at specialist clinics and some cardiology departments. Standard blood pressure measurement captures downstream effects of this stiffness, but blood pressure often rises only after years of arterial wall changes; women who have blood pressure readings creeping toward the high-normal range (120–129/under 80) in early postmenopause should flag this trend with their clinician, as it often reflects this vascular transition rather than incidental hypertension.
Coronary Artery Calcium (CAC) Score — Seeing Plaque Before It Becomes a Problem
A coronary artery calcium score is a low-radiation CT scan that directly measures calcified plaque in the coronary arteries — actual physical evidence of atherosclerosis rather than an indirect blood marker. Data from the Women's Health Initiative and other cohort studies confirm that the rate of CAC progression accelerates around the time of menopause, independent of traditional risk factors. A CAC score of zero in a postmenopausal woman is genuinely reassuring and can inform a shared decision to defer medication; a score above zero changes the risk conversation substantially, which is why cardiovascular societies now endorse it as a tiebreaker test in women with intermediate risk.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.